Chinese Capital Accesses Western Innovation To Create Homegrown Industry
Executive Summary
With the Chinese market growing at 10-15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains how Chinese capital is accessing Western innovation to build a PRC pharma industry.
You may also be interested in...
BioBay Center To Help Medtech Firms Enter China
With the aim of helping western companies tap into the fast-growing Chinese healthcare market, a new cross-border medical technology commercialization center planned in the Suzhou BioBay cluster will provide funding and assistance to selected U.S. and European companies for all aspects of product registration and commercialization in China.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.